Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 New Psoriasis Indication in EU for Humira | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

New Psoriasis Indication in EU for Humira

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott has received marketing authorization from the European Commission for the use of Humira as a treatment for moderate-to-severe plaque psoriasis. In one clinical trial, more than 80%  of patients taking Humira achieved skin clearance of 75%  or better and in another, almost three quarters of patients achieved 75% clearance. In both trials, nearly half of the patients taking HUMIRA achieved 90% clearance as early as 16 weeks into treatment.

Psoriasis is the fifth approved indication for Humira in the EU. Humira is the first fully human, self-injectable biologic for the treatment of psoriasis. The FDA is reviewing the drug for the same indiciation.

Psoriasis is a non-contagious, chronic autoimmune disease that causes the body to attack itself. The most obvious physical symptom of the condition is raised, inflamed, scaly, red skin lesions known as plaques, which may crack and bleed. Psoriasis is more than painful skin lesions; data also suggest an association with other health conditions, including psoriatic arthritis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters